{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T19:21:48Z","timestamp":1772306508308,"version":"3.50.1"},"reference-count":25,"publisher":"Impact Journals, LLC","issue":"47","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,10,10]]},"DOI":"10.18632\/oncotarget.19970","type":"journal-article","created":{"date-parts":[[2017,8,7]],"date-time":"2017-08-07T10:19:01Z","timestamp":1502101141000},"page":"82897-82909","source":"Crossref","is-referenced-by-count":20,"title":["Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant <i>KIT<\/i> D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia"],"prefix":"10.18632","volume":"8","author":[{"given":"Kerstin Maria","family":"Kampa-Schittenhelm","sequence":"first","affiliation":[{"name":"University Hospital T\u00fcbingen, Department of Oncology, Hematology, Rheumatology, Clinical Immunology and Pulmology, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Frey","sequence":"additional","affiliation":[{"name":"University Hospital T\u00fcbingen, Department of Oncology, Hematology, Rheumatology, Clinical Immunology and Pulmology, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara A.","family":"Haeusser","sequence":"additional","affiliation":[{"name":"University Hospital T\u00fcbingen, Department of Oncology, Hematology, Rheumatology, Clinical Immunology and Pulmology, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Illing","sequence":"additional","affiliation":[{"name":"University Hospital T\u00fcbingen, Department of Oncology, Hematology, Rheumatology, Clinical Immunology and Pulmology, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashly A.","family":"Pavlovsky","sequence":"additional","affiliation":[{"name":"Arog Pharmaceuticals, Inc., Dallas, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Blumenstock","sequence":"additional","affiliation":[{"name":"Institute of Clinical Epidemiology and Applied Biometry, Eberhard Karls University T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus Matthias","family":"Schittenhelm","sequence":"additional","affiliation":[{"name":"University Hospital T\u00fcbingen, Department of Oncology, Hematology, Rheumatology, Clinical Immunology and Pulmology, T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,8,7]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Metcalfe","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1182\/asheducation-2015.1.98","article-title":"Diagnosis and management of mastocytosis: an emerging challenge in applied hematology","volume":"2015","author":"Valent","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V95.2.726","article-title":"C-kit mutations in core binding factor leukemias","volume":"95","author":"Mecucci","year":"2000","journal-title":"Blood"},{"key":"4","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1200\/JCO.2006.06.9500","article-title":"Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study","volume":"24","author":"Bloomfield","year":"2006","journal-title":"J Clin Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Verstovsek","year":"2009","journal-title":"Leuk Res"},{"key":"6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1365-2125.2009.03466.x","article-title":"Effect of a proton pump inhibitor on the pharmacokinetics of imatinib","volume":"68","author":"Beumer","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"7","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Kantarjian","year":"2008","journal-title":"Clin Cancer Res"},{"key":"8","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Stanek","year":"2016","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0163-7258(99)00005-4","article-title":"Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent","volume":"82","author":"Meyer","year":"1999","journal-title":"Pharmacol Ther"},{"key":"10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/JBM.S100283","article-title":"Midostaurin: an emerging treatment for acute myeloid leukemia patients","volume":"7","author":"Lazarus","year":"2016","journal-title":"J Blood Med"},{"key":"11","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1158\/1078-0432.CCR-12-0625","article-title":"Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors","volume":"18","author":"Debiec-Rychter","year":"2012","journal-title":"Clin Cancer Res"},{"key":"12","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1182\/blood-2013-07-513044","article-title":"Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia","volume":"122","author":"Baker","year":"2013","journal-title":"Blood"},{"key":"13","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.3324\/haematol.2014.117028","article-title":"Inhibition of c-Kit by tyrosine kinase inhibitors","volume":"100","author":"Levis","year":"2015","journal-title":"Haematologica"},{"key":"14","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1073\/pnas.1320661111","article-title":"Crenolanib is a selective type I pan-FLT3 inhibitor","volume":"111","author":"Shah","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"15","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412","volume":"106","author":"Gilliland","year":"2005","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies","volume":"66","author":"Heinrich","year":"2006","journal-title":"Cancer Res"},{"key":"17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2013-10-529313","article-title":"Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants","volume":"123","author":"Levis","year":"2014","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1038\/sj.leu.2404374","article-title":"FLT3 K663Q is a novel AML-associated oncogenic kinase: determination of biochemical properties and sensitivity to Sunitinib (SU11248)","volume":"20","author":"Heinrich","year":"2006","journal-title":"Leukemia"},{"key":"19","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1182\/blood-2003-10-3381","article-title":"Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells","volume":"104","author":"Heinrich","year":"2004","journal-title":"Blood"},{"key":"20","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.4161\/cc.8.16.9355","article-title":"The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin","volume":"8","author":"Heinrich","year":"2009","journal-title":"Cell Cycle"},{"key":"21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1476-4598-12-19","article-title":"Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms","volume":"12","author":"Schittenhelm","year":"2013","journal-title":"Mol Cancer"},{"key":"22","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2006-04-015743","article-title":"Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors","volume":"108","author":"Wang","year":"2006","journal-title":"Blood"},{"key":"23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12885-015-2029-8","article-title":"Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns","volume":"16","author":"Schittenhelm","year":"2016","journal-title":"BMC Cancer"},{"key":"24","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/01.pas.0000138181.89743.7b","article-title":"CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens","volume":"28","author":"Valent","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Sawyers","year":"2002","journal-title":"Cancer Cell"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T13:24:13Z","timestamp":1589203453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,7]]},"references-count":25,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2017,10,10]]}},"alternative-id":["19970","29137311"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.19970","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,7]]}}}